98 results about "Diabetes diagnosis" patented technology

Low-level laser therapy is applied externally through the skin of the patient to targeted areas of a of a patient's body to treat diabetes or prediabetes. A patient is first diagnosed with diabetes or prediabetes, preferably by blood draws that measure insulin, A1C, or glucose levels. A therapeutic amount of laser energy to apply is determined from a patient's biological factors such as body mass index. The therapeutic amount of laser energy is applied one or more times over a two week time period. The patient is then retested for diabetes or prediabetes. If necessary, a new therapeutic amount of laser energy is determined according to any changes in the patient's diabetes or prediabetes diagnosis and any changes in the patient's biological factors. Adjusted treatments with low-level laser energy continue until the diabetes or prediabetes diagnosis is removed.

An apparatus and method for monitoring diabetes through breath acetone detection and quantitation employs a microplasma source in combination with a spectrometer. The microplasma source provides sufficient energy to produce excited acetone fragments from the breath gas that emit light. The emitted light is sent to the spectrometer, which generates an emission spectrum that is used to detect and quantify acetone in the breath gas.

The invention discloses an Au NPs-CeO2@PANI nanocomposite, a preparation method thereof and a glucose biological sensor manufactured by utilizing the nanocomposite. Firstly, the Au NPs-CeO2@PANI nanocomposite is composited by utilizing cerium dioxide (CeO2) nano particles, aniline (An) monomers and aurum (Au) nano particles; and the Au NPs-CeO2@PANI nanocomposite is fixed with glucose oxidase, soas to manufacture the glucose biological sensor. The nanocomposite prepared in the invention has a good compatibility and is favourable for fixing bioenzyme; the cost of the preparation method is low, and the preparation method is simple and fast. The biological sensor manufactured in the invention has the advantages of high sensitivity, good stability and wide linear range, and has a certain capacity for resisting interference, therefore the biological sensor can be widely used in the fields of diabetes diagnosis and food process monitoring. The linear range for detecting diabetes is 6.2*10<-6> to 2.8*10<-3>M, and the detection limit is 1.0*10<-6>M.

The invention provides a polypeptide marker for early diagnosis of diabetes mellitus. The operating method comprises the following steps: establishing an in-vitro simulated glycosylation model by selecting human peripheral blood high-abundant protein HAS, performing enzyme digestion under optimized conditions, performing 18O marking on a blank control group sample subjected to enzyme digestion, mixing the blank control group sample with a reaction group sample subjected to parallel treatment by using 16O according to a volume percent of 1:1, and performing HPLC/ESI-TOFMS detection. According to quantitative analysis of HSA peptide fragments, a peptide fragment, which is the most difficultly modified by glucose and is shown as SEQ ID NO.1, serves as an internal standard peptide fragment, a ratio of a peptide fragment which is easily subjected to glycosylation modification to the peak area of the internal standard peptide fragment is used for measuring the glycosylation modification degree of a glucose sensitive peptide, and according to a proteomics method, three peptide fragments, namely FKDLGEENFK, LDELRDEGK and KVPQVSTPTLVEVSR are finally discovered to serve as biological markers to be used for early diagnosis of diabetes mellitus.

The invention provides compounds and methods useful for the diagnosis, prediction, therapy, or prophylaxis of type 1 diabetes. The compounds of the invention include peptides derived from IAPP (islet amyloid polypeptide) precursor peptides.

The present invention relates to a diagnostic agent for diabetes, comprising a compound labelled with 13C at least at one specific position selected from the group consisting of the following (a) to (g):(a) galactose, fructose or xylose labelled with 13C at least atone specific position, or a starch composed of glucose units labelled with 13C at least at one specific position;(b) an amino acid labelled with 13C at least at one specific position;(c) lactic acid or citric acid labelled with 13C at least at one specific position;(d) a fatty acid labelled with 13C at least at one specific position;(e) a glyceride labelled with 13C at least at one specific position;(f) glycerol labelled with 13C at least at one specific position; and(g) aminopyrin of which the dimethylamino group at position 4 is labelled with 13C, phenacetin of which the ethoxy group is labelled with 13C at position 1, or methacetin of which the methoxy group is labelled with 13C.According to the present invention, there is provided a diagnostic agent for diabetes which does not impose a heavy physical burden on a subject, can give accurate test results immediately and can be used safely without side effects. The diagnostic agent of the invention makes it possible to discriminate patients with diabetes from normal subjects even under circumstances where patients are easily missed.

The invention relates to a method of detecting glucose by a nickel oxide nanoparticles and carbon nanofibers composite (NiONPs-CNFs) modified electrode, namely modification of supported nickel oxide nanoparticle carbon nanofiber layer on the surface of a conventional electrode. The method includes: subjecting carbon nanofibers of supported nickel oxide nanoparticles to even ultrasonic dispersion in solvent, dispensing the dispersion liquid to the surface of the conventional clean electrode, airing at the room temperature, performing cyclic voltammetry activation in NaOH solution to obtain the high-sensitivity non-enzymatic glucose electrochemical sensor. The production method of nano composites is simple, fast and low in cost; the produced electrochemical sensor is high in sensitivity, fine in stability, wide in linear range, and fine in repeatability. The sensor is expectedly widely applied to the fields of diagnosis of diabetes mellitus, clinical medicine, food technologies and detection and the like.

The invention discloses a tongue diagnosis system for screening diabetes. The tongue diagnosis system comprises a tongue picture instrument, a tongue picture parameter obtaining module, a blood glucose parameter and tongue picture parameter correlation analysis module, a multiple regression mathematic model establishing module and a diabetes suffering value tangency point determining module, wherein the tongue picture parameter obtaining module is used for receiving a tongue picture image collected by the tongue picture instrument and obtaining tongue picture parameters; the blood glucose parameter and tongue picture parameter correlation analysis module is used for receiving the tongue picture parameters, carrying out correlation analysis on the tongue picture parameters and blood glucose parameters and obtaining tongue picture parameters related to glycometabolism; the multiple regression mathematic model establishing module is used for receiving the tongue picture parameters related to the glycometabolism and establishing a multiple regression mathematic model; the diabetes suffering value tangency point determining module is used for collecting the tongue picture parameters, comparing the tongue picture parameters with a golden standard of a diabetes diagnosis method and determining a diabetes suffering value tangency point. The tongue diagnosis system disclosed by the invention has better accuracy and flexibility in diabetes screening, and compared with a traditional method, the tongue diagnosis system is simpler, more convenient and economic and is good in practicability.

The invention involves methods, compositions, and kits for detecting glycated proteins in a sample (e.g., urine or other bodily fluid) from a subject. Also provided are methods, compositions, and kits for diagnosing or following a diabetic condition of the subject or screening for a diabetic condition in a population of subjects based upon the detection of the glycated protein(s) in the sample.

he present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes.

The invention relates to the technical field of biology, and in particular relates to a kit for combined detection of 6 diabetic antibodies. The kit is used for combined detection of 6 antibodies such as ICA, GADA, IAA, IA-2ACPH-A and ZnT8-A in T1DM, T2DM and serum of a normal person, has high sensitivity (98 percent) and specificity (99.6 percent) for I type diabetic diagnosis, and provides efficient and fast detection means for classificatory diagnosis of diabetes.

The present invention provides an impaired glucose tolerance ameliorating drug and a therapeutic drug for lifestyle-related diseases, particular an antidiabetic drug, which contain a CXCR3 agonist as an active ingredient; a hypoglycemia ameliorating drug, a therapeutic drug for insulinoma or an anti-obesity drug containing a CXCR3 antagonist as an active ingredient; a method of screening for a new CXCR3 ligand using CXCR3 and a known CXCR3 ligand; a method of screening a CXCR3 ligand, which uses a co-expression system of CXCR3 and a coupling G protein; and a diagnostic method for type II diabetes, which includes detecting an amount of a CXCR3 ligand expressed in a biological sample.

The invention provides a high-sensitivity glucose electrochemical sensor which is obtained by modifying the surface of a conventional electrode with a layer of a palladium-platinum alloy loaded carbon nanofiber composite, i.e., a sensitive film of PdPt-CNFs. A preparation method for the electrochemical sensor comprises the following steps: dispersing palladium-platinum alloy loaded carbon nanofibers in a solvent through ultrasonic dispersion to obtain a uniform dispersion liquid; dropwise coating the dispersion liquid on the surface of a conventional clean electrode; evaporating the solvent; then immobilizing glucose oxidase; and after air-drying at room temperature, carrying out cross-linking above a glutaraldehyde saturated vapor pressure liquid level so as to obtain the high-sensitivity glucose electrochemical sensor. According to the invention, the prepared nanocomposite has good biocompatibility and is beneficial for immobilization of biological enzyme, and the preparation method is simple and fast and has low cost; the electrochemical sensor prepared in the invention has high sensitivity and good stability and reproducibility, so the electrochemical sensor is expected to be widely used in fields like diagnosis of diabetes, clinical medicine and food process checking.

The invention discloses an electrode surface modifying material as well as a preparation method and an application thereof, particularly relates to a dispersion liquid formed by dispersing polyvinylpyrrolidone-functionalized graphene-loaded nickel nano particles (PVP-GR/NiNPs) in a chitosan solution and a preparation method of the dispersion liquid. The dispersion fluid is dispensed on a regular clean electrode surface, dried under an infrared lamp, and activated by cyclic voltammetry in a NaOH solution to obtain a high-sensitivity enzyme-free glucose electrochemical sensor for glucose detection. The preparation method of the nano composite material disclosed by the invention is simple and quick, low in cost, and good in stability; and the prepared electrochemical sensor is high in sensitivity, wide in linear range and good in repeatability. The electrode surface modifying material is expected to be widely applied in the fields such as diagnosis of diabetes mellitus, clinical medicine and food process detection.

The invention provides a preparation method of an enzyme-free glucose electrochemical sensor electrode. The method comprises the steps that gamma-Al2O3 powders are sequentially utilized to polish the surface of a glassy carbon electrode, and ultrasonic washing is conducted; the electrode is immersed into a certain concentration of mixed solution of KMnO4 and H2SO4, the scanning speed is set, two circles of cycle-scanning is conducted under the voltage range from 0.3 V to -0.5 V to prepare a MnO2/glassy carbon electrode; the electrode is put into a KCl solution containing a certain concentration of NiCl2, the pH value of the solution is adjusted to 7.00, the scanning speed is set, electro-deposition is conducted for 100-250 s under the voltage range from 0.9 V to -0.9 V, and the enzyme-free glucose electrochemical sensor electrode is obtained. According to the preparation method of the enzyme-free glucose electrochemical sensor electrode, common metal and metal oxide are adopted, the preparation technology is simple, the cost is low, the sensitivity is high, the stability is good, the service life is long, and the linearity range is wide. The preparation method of the enzyme-free glucose electrochemical sensor electrode is expected to be widely applied in the fields such as diabetes diagnosis, clinical medicine and food technology detection.

The invention belongs to the field of biological detection and particularly relates to an LncRNA marker and application of the LncRNA marker to diabetes. It is successfully detected that the LncRNA marker NONHSAT024449 has the obvious expression difference in blood of diabetic patients, compared with a normal crowd contrast group, the patients of a diabetic crowd experiment group have the low-expression LncRNA marker NONHSAT024449, and based on the discovery, the LncRNA marker NONHSAT024449 can serve as a diabetes molecular marker or target to be applied to diabetes clinical diagnosis or targeted therapy; by detecting a specific primer pair of the LncRNA marker NONHSAT024449, early screening and prevention of diabetes/evaluation of the occurrence risk of diabetes can be realized; and by applying the LncRNA marker NONHSAT024449 to preparation of a diabetes diagnosis product or a diabetes prevention/ evaluation product, diabetes occurrence and development mechanisms, signal channels andthe like are further illuminated advantageously, and the LncRNA marker extremely has application prospects and theoretical value.

A system and method of evaluating and treating diabetes ensures a consistent and enduring path for overcoming diabetes and maintaining a healthy lifestyle. The system required in order to implement the method includes at least one remote server and a corresponding personal (PC) computing device. At least one user account is managed by the at least one remote server and is associated with a corresponding PC device. The overall process begins with a diabetes diagnosis process that determines which type of diabetes is associated with user account. A medical assessment process and a self-management process are interchangeably executed after the diabetes diagnosis process. A risk stratification process then determines how to treat the user account. A clinical prescription process follows, then a behavioral health process, a continuous monitoring process, and a professional follow-up process are interchangeably executed after.

The invention discloses a construction method of a diabetic cardiomyopathy animal model. An SD (Sprague Dawley) rat under high-sugar and high-fat feeding is subjected to multiple abdominal injection with STZ (streptozocin); after the diabetics diagnosis standard is reached, subcutaneous injection with isoprenaline is performed; after 2 weeks of continued feeding, left ventricular cannulation and three-lead electrocardiogram test of ventricular hemodynamic parameters and electrocardiogram parameters shows that the rat experiences cardiac dysfunction; heart weight index and left ventricular index show that the rat experiences evident ventricular hypertrophy; biochemical analysis on rat blood shows that the rat has evident myocardial damage; HE (hematoxylin-eosin) pathological staining satisfies pathological changes in diabetic cardiomyopathy; Masson collagen staining satisfies myocardial connective tissue proliferation of diabetic cardiomyopathy. The construction method has the advantages of good operational simplicity, short construction time, low mortality in construction phase, high construction success rate and the like, and the pathological process of myocardial damage due to human type 2 diabetes mellitus can be well simulated.

The invention relates to the field of medical diagnosis, in particular to biomarkers which are screened by metabonomics and are used for identifying and diagnosing gestational diabetes mellitus, and a model which is used for diagnosing whether a gestational individual is diabetes mellitus or not is established according to the biomarkers. The invention provides a biomarker and a diagnostic model for differential diagnosis of gestational diabetes mellitus, which can be applied to early diagnosis or prediction of gestational diabetes mellitus and have important significance in prevention or treatment of gestational diabetes mellitus.

The invention discloses a diabetes diagnosis model construction method based on eye image recognition and electronic equipment. The construction method specifically comprises the steps of obtaining multiple groups of binocular image images of a crowd based on the electronic equipment; preprocessing each group of binocular image images to obtain sclera images and iris images of each group of binocular image images, and constructing a training sample set based on all sclera images and iris images; constructing a first-step classifier by using the unhealthy samples and the healthy samples in the training sample set; constructing a second-step classifier by using other disease samples and diabetes samples in the training sample set; and integrating the classifier in the first step and the classifier in the second step to obtain a diabetes diagnosis model. According to the scheme, the diabetes diagnosis model which is a diagnostic tool for eye diagnosis can be obtained, diabetes diagnosis is carried out on a patient based on objective standards without depending on naked eye observation and personal experience of a doctor, and the stability of diabetes eye diagnosis is improved.